The estimated Net Worth of Venture Fund V Lpatlas Vent... is at least 199 百万$ dollars as of 23 February 2006. Venture Vent owns over 183,000 units of Alnylam Pharmaceuticals Inc stock worth over 195,798,678$ and over the last 19 years Venture sold ALNY stock worth over 2,730,360$.
Venture has made over 1 trades of the Alnylam Pharmaceuticals Inc stock since 2006, according to the Form 4 filled with the SEC. Most recently Venture sold 183,000 units of ALNY stock worth 2,730,360$ on 23 February 2006.
The largest trade Venture's ever made was selling 183,000 units of Alnylam Pharmaceuticals Inc stock on 23 February 2006 worth over 2,730,360$. On average, Venture trades about 183,000 units every 0 days since 2006. As of 23 February 2006 Venture still owns at least 747,580 units of Alnylam Pharmaceuticals Inc stock.
You can see the complete history of Venture Vent stock trades at the bottom of the page.
Over the last 20 years, insiders at Alnylam Pharmaceuticals Inc have traded over 140,068,015$ worth of Alnylam Pharmaceuticals Inc stock and bought 4,419,116 units worth 1,983,132,563$ . The most active insiders traders include Sanofi、Christoph H Westphal、Kevin P Starr. On average, Alnylam Pharmaceuticals Inc executives and independent directors trade stock every 23 days with the average trade being worth of 11,181,724$. The most recent stock trade was executed by Yvonne Greenstreet on 20 August 2024, trading 15,000 units of ALNY stock currently worth 1,275,000$.
alnylam is developing an entirely new class of innovative medicines based on a breakthrough discovery in biology known as rna interference, or rnai. with rnai technology, we have the opportunity to treat disease and impact the lives of patients in a fundamentally new way by silencing disease-causing genes upstream of today's medicines.
Alnylam Pharmaceuticals Inc executives and other stock owners filed with the SEC include: